Leukemia is an umbrella term that includes acute and chronic lymphoblastic leukemia (ALL, CLL) and acute and chronic myeloid leukemia (AML, CML).
Depending on the indication, these diseases are currently treated with a combination of therapies including chemotheraputic agents (such as cytarabine and decitabine), targeted therapies (such as PI3K, BTK and Bcr-Abl inhibitors), monoclonal antibodies, and the recently developed CAR-T therapies. Immuno-oncology therapy is another method of treatment. Immuno-oncology treatments activate the immune system and makes it possible to detect cancer cells and destroy them.
Overall, depending on the subindication, a significant unmet medical need remains, and a great deal of hope is placed in the development of novel innovative therapies. In 2016, there were approximately 12,310 cases of CML in the United States, Japan and the five major markets in the EU (France, Germany, Italy, Spain and the United Kingdom). The number of incident cases is projected to grow by 32,7 percent and reach 16,330 by 2036 (source: Datamonitor).
The AML market was valued at approximately MUSD 700 in 2018 and is projected to reach MUSD 1,540 by 2024, corresponding to a CAGR of 14 percent. In 2017, the sales of important CLL drugs in the United States, Japan and five major markets in the EU amounted to USD 4.2 billion. The value of these markets is expected to increase to USD 8.0 billion by 2026 (source: Datamonitor).